VRTX Q4 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.2B+10.8% YoY

Gross Profit

$2.8B85.6% margin

Operating Income

$1.3B40.3% margin

Net Income

$1.2B36.9% margin

EPS (Diluted)

$4.65

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

$498M

Free Cash Flow

$349M

Stock-Based Comp.

$158M

Balance Sheet

Total Assets

$26.1B

Total Liabilities

$7.5B

Stockholders' Equity

$18.7B

Cash & Equivalents

$5.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.2B	$2.9B	+10.8%
Gross Profit	$2.8B	$2.5B	+10.9%
Operating Income	$1.3B	$1.0B	+26.7%
Net Income	$1.2B	$913M	+30.5%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.6B81%

ALYFTREK

$380M12%

Manufactured Product, Other

$237M7%

Geographic Segments

Non-US

$4.1B58%

UNITED STATES

$2.1B30%

Europe

$886M13%